MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- BIOCON - CADILA HEALTHCARE
BIOCON vs CADILA HEALTHCARE - Comparison Results
BIOCON 
Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
CADILA HEALTHCARE
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Current Valuations
| BIOCON | CADILA HEALTHCARE | BIOCON / CADILA HEALTHCARE |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.0 | 13.6 | 133.0% | View Chart |
| P/BV | x | 2.8 | 2.8 | 100.1% | View Chart |
| Dividend Yield | % | 0.4 | 1.4 | 28.2% |
Financials
 BIOCON  CADILA HEALTHCARE |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-18 |
CADILA HEALTHCARE Mar-18 |
BIOCON / CADILA HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,188 | 558 | 212.9% | |
| Low | Rs | 305 | 362 | 84.4% | |
| Sales per share (Unadj.) | Rs | 68.7 | 116.3 | 59.1% | |
| Earnings per share (Unadj.) | Rs | 7.6 | 17.9 | 42.3% | |
| Cash flow per share (Unadj.) | Rs | 14.0 | 23.1 | 60.4% | |
| Dividends per share (Unadj.) | Rs | 1.00 | 3.50 | 28.6% | |
| Dividend yield (eoy) | % | 0.1 | 0.8 | 17.6% | |
| Book value per share (Unadj.) | Rs | 86.3 | 85.4 | 101.1% | |
| Shares outstanding (eoy) | m | 600.00 | 1,023.74 | 58.6% | |
| Bonus/Rights/Conversions | IS | - | - | ||
| Price / Sales ratio | x | 10.9 | 4.0 | 274.8% | |
| Avg P/E ratio | x | 98.9 | 25.7 | 384.2% | |
| P/CF ratio (eoy) | x | 53.4 | 19.9 | 268.8% | |
| Price / Book Value ratio | x | 8.6 | 5.4 | 160.6% | |
| Dividend payout | % | 13.2 | 19.6 | 67.6% | |
| Avg Mkt Cap | Rs m | 447,900 | 470,664 | 95.2% | |
| No. of employees | `000 | 6.1 | 11.8 | 52.0% | |
| Total wages/salary | Rs m | 9,311 | 18,545 | 50.2% | |
| Avg. sales/employee | Rs Th | 6,705.8 | 10,072.7 | 66.6% | |
| Avg. wages/employee | Rs Th | 1,514.2 | 1,569.1 | 96.5% | |
| Avg. net profit/employee | Rs Th | 736.9 | 1,547.7 | 47.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 41,234 | 119,049 | 34.6% | |
| Other income | Rs m | 2,062 | 1,132 | 182.2% | |
| Total revenues | Rs m | 43,296 | 120,181 | 36.0% | |
| Gross profit | Rs m | 8,291 | 28,475 | 29.1% | |
| Depreciation | Rs m | 3,851 | 5,388 | 71.5% | |
| Interest | Rs m | 615 | 911 | 67.5% | |
| Profit before tax | Rs m | 5,887 | 23,308 | 25.3% | |
| Minority Interest | Rs m | 213 | 628 | 33.9% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,569 | 5,644 | 27.8% | |
| Profit after tax | Rs m | 4,531 | 18,292 | 24.8% | |
| Gross profit margin | % | 20.1 | 23.9 | 84.1% | |
| Effective tax rate | % | 26.7 | 24.2 | 110.1% | |
| Net profit margin | % | 11.0 | 15.4 | 71.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 41,486 | 82,005 | 50.6% | |
| Current liabilities | Rs m | 21,413 | 60,720 | 35.3% | |
| Net working cap to sales | % | 48.7 | 17.9 | 272.3% | |
| Current ratio | x | 1.9 | 1.4 | 143.5% | |
| Inventory Days | Days | 64 | 73 | 87.5% | |
| Debtors Days | Days | 94 | 98 | 95.8% | |
| Net fixed assets | Rs m | 50,661 | 83,703 | 60.5% | |
| Share capital | Rs m | 3,000 | 1,024 | 293.0% | |
| "Free" reserves | Rs m | 48,808 | 86,421 | 56.5% | |
| Net worth | Rs m | 51,808 | 87,445 | 59.2% | |
| Long term debt | Rs m | 17,898 | 25,551 | 70.0% | |
| Total assets | Rs m | 99,897 | 180,653 | 55.3% | |
| Interest coverage | x | 10.6 | 26.6 | 39.8% | |
| Debt to equity ratio | x | 0.3 | 0.3 | 118.2% | |
| Sales to assets ratio | x | 0.4 | 0.7 | 62.6% | |
| Return on assets | % | 5.2 | 10.6 | 48.5% | |
| Return on equity | % | 8.7 | 20.9 | 41.8% | |
| Return on capital | % | 9.6 | 22.0 | 43.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 12,058 | 42,683 | 28.3% | |
| Fx outflow | Rs m | 7,348 | 11,242 | 65.4% | |
| Net fx | Rs m | 4,710 | 31,441 | 15.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,621 | 9,193 | 72.0% | |
| From Investments | Rs m | -6,840 | -9,737 | 70.2% | |
| From Financial Activity | Rs m | -2,397 | 515 | -465.4% | |
| Net Cashflow | Rs m | -2,612 | -29 | 9,006.9% | |
Share Holding
| Indian Promoters | % | 40.4 | 74.8 | 54.0% | |
| Foreign collaborators | % | 20.6 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.4 | 8.3 | 101.2% | |
| FIIs | % | 10.7 | 5.9 | 181.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 19.9 | 11.0 | 180.9% | |
| Shareholders | 109,995 | 44,069 | 249.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: FDC LTD. UNICHEM LAB DR. REDDYS LAB DIVIS LABORATORIES ALEMBIC LTD
Compare BIOCON With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 491 Points Lower; Metal and Energy Stocks Witness Selling(Closing)
After opening the day marginally lower, share markets in India witnessed negative trading activity throughout the day and ended deep in the red.
Related Views on News
CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)
Jun 6, 2019Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...
FM Nirmala Sitharaman Inherits an Economy Facing a Number of Headwinds(Sector Info)
Jun 4, 2019The Indian economy is in a major slowdown. Will the new finance minister, Nirmala Sitharaman bring the much-needed reforms?
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
More|
| |
BIOCON SHARE PRICE
Jun 17, 2019 (Close)
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON 8-QTR ANALYSIS
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.